The size of the global market for Eubiotics is expected to reach USD 10.08 Billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.4%.
.jpg
"The Global Eubiotics Market 2020-2030 (USD Billion)")
The global eubiotics market was valued at USD 4.82 billion in 2020 and is projected to grow at a CAGR of 7.8% during the forecast period. Factors driving the growth of the eubiotics market include growing cognizance about feed quality and safety, ban on the use of antibiotics as growth promoters and high demand for safe human food.
The global eubiotics market is segmented based on type, livestock, function and form. Type is further split into probiotics, prebiotics, organic acids, and essential oils. The probiotics segment dominated the market in 2019. On the basis of livestock, the market is segmented into swine, poultry, ruminants, aquatic animals, and others. The poultry segment was the largest market in 2019. By function, the market is segmented into nutrition & gut health, yield, immunity, and productivity. The nutrition & gut health segment accounted for the largest share. By form, the market is segmented into dry and liquid. The dry form dominated the market in 2019 and is expected to retain its position by 2028.
Regionally, Europe accounted for the largest market share of the global eubiotics market attributable to biotechnological innovations for eubiotic products. Leading players of the global eubiotics market include Cargill, E. I. du Pont de Nemours and Company, BASF SE, Koninklijke DSM N. V., Novozymes, Chr. Hansen A/S, Calpis Co., Ltd., Kemin Industries, Inc., Lesaffre Group, Lallemand Inc., among others.
Eubiotics Market Scope
| Metrics | Details |
| Base Year | 2023 |
| Historic Data | 2018-2022 |
| Forecast Period | 2024-2030 |
| Study Period | 2018-2030 |
| Forecast Unit | Value (USD) |
| Revenue forecast in 2030 | USD 10.08 Billion |
| Growth Rate | CAGR of 7.4% during 2020-2030 |
| Segment Covered | By Type, Regions |
| Regions Covered | North America, Europe, Asia Pacific, South America, Middle East and Africa |
| Key Players Profiled | BASF SE, ADDCON, Novus International Inc., Kemin Industries Inc., Calpis Co. Ltd., Koninklijke DSM NV, Novozymes, Lesaffre Group, Behn Mayer Group, Cargill, Chr. Hansen Holding A/S, Lallesmand Inc., and Advanced Bio Nutrition Corp. |
Key Segment Of The Eubiotics Market
By Type,(USD Billion)
• Probiotics
• Prebiotics
• Organic Acids
• Essential Oils
By Form,(USD Billion)
• Dry
• Liquid
By Livestock,(USD Billion)
• Poultry
• Swine
• Ruminants
• Aquatic animals
• Others (horses, sheep, and birds)
Regional Overview,(USD Billion)
North America
• US
• Canada
Europe
• Germany
• France
• UK
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• Rest of Asia Pacific
South America
• Mexico
• Brazil
• Rest of South America
Middle East and South Africa
Frequently Asked Questions (FAQ) :
The market value of eubiotics market in 2030 was USD 10.08 Billion
The base year for the report is 2023 in eubiotics market
The major contenders in the global eubiotics marketBASF SE, ADDCON, Novus International Inc., Kemin Industries Inc., Calpis Co. Ltd., Koninklijke DSM NV, Novozymes, Lesaffre Group, Behn Mayer Group, Cargill, Chr. Hansen Holding A/S, Lallesmand Inc., and Advanced Bio Nutrition Corp.
The key issue which precipitated the ban was the growing problem of antimicrobial resistance in human medicine. While it is generally accepted that the greater majority of the resistance originates from medical use to treat human disease, concerns were expressed that the use of antimicrobials in animals may be a contributory factor to human resistance. The tightening restrictions on the use of AGPs, the mounting consumer pressure on food safety and the changing consumer preference are the key drivers to the search for viable alternatives to in-feed antibiotics. Several well researched eubiotics have shown promising results in university and field trials and have eventually been successfully used in commercial conditions. Organic acids like benzoic acid, essential oil compounds, probiotics and nucleotides can be used either as single products or one can combine two or more eubiotics to achieve a higher response. While there has been a number of research studies on the effect of eubiotics, more need to be conducted to fully understand how they act and how farmers can get the most out of their use to maintain gut health and reduce the need for antibiotic treatment.
On the basis of livestock, the eubiotics market is segmented into swine, poultry, ruminants, aquatic animals, and others, which include horses, sheep, and birds. Despite being beset with a host of diseases, global pig production continues to grow, especially in Asia. However, with the spiraling feed raw material prices, farmers are constantly finding ways to maximize the genetic potential of pigs and one of these measures is to maintain a healthy gut. While in the past, farmers relied heavily on AGPs in modulating the intestinal ecosystem, the banning of AGPs in Europe has intensified the search for alternatives to antibiotics.
For the affluent consumers in the West, particularly in Europe, animal welfare, quality, safety and sustainability are important considerations. Retailers on the other hand are keeping close tabs on these developments and for them traceability and certifications are a must to stay in business. In the USA, the evolution is less marked than in Europe although organic production is increasing as consumers in large US cities are demanding more natural products. The high profile food scandals and diseases have driven the public to look for safety which they trust the FDA/USDA to ensure. Two major companies have started marketing ‘antibiotic-free meat’. All these consumer demands come with a price tag; hence both in the USA and Europe the retail price is still a key decision parameter especially during crisis times.